MMED (NASDAQ:MMED) Earns Neutral Rating from Analysts at Piper Sandler

Research analysts at Piper Sandler started coverage on shares of MMED (NASDAQ:MMED) in a report released on Tuesday. The firm set a “neutral” rating and a $16.00 price target on the stock. Piper Sandler’s price objective would indicate a potential upside of 11.50% from the company’s current price.

A number of other equities research analysts have also weighed in on the stock. BTIG Research started coverage on shares of MMED in a report on Tuesday. They set a “buy” rating and a $25.00 price objective for the company. Bank of America initiated coverage on shares of MMED in a research report on Tuesday. They set a “buy” rating and a $27.00 target price on the stock. Finally, Wall Street Zen raised shares of MMED to a “hold” rating in a research note on Saturday, March 14th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.33.

MMED Trading Down 0.8%

Shares of MMED stock opened at $14.35 on Tuesday. MMED has a 52 week low of $14.10 and a 52 week high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.